2 ms·
Genetics-specific treatment is what medicine should be working toward. Currently it is structured to make-pill-mint-money for drug companies. If a disease/trea
by AtlasBarfed 7y ago
Genetics-specific treatment is what medicine should be working toward.
Currently it is structured to make-pill-mint-money for drug companies. If a disease/treatment isn't mass produced, THEY DON'T CARE.
Medical devices are a bit closer to what is needed, but fundamentally they are run by the same business models.
Instead what will probably be required is a lot of specific testing (labor intensive), computational analysis (some labor and analysis) that produces the necessary treatment formula (or CRISPR design, etc), and then something that produces it.
The margins won't be great, so no MBA-driven healthcare will care about that.
The biggest disease that needs this approach to approach a "cure": CANCER. Cancer, even the "common" ones, are the result of dozens of varieties/combinations of gene malfunctions.
First world nations should pool money to start a multinational infrastructure that includes continuous improvement. Sections of this can probably be make profitable, but those will probably be lots of small companies.
All of which would be GREAT for employment.
- dmix 7y agoI don't see why you repeatedly accuse MBA people or the pharma scientists of not "caring" then proceed to explain multiple reasons why it's infeasible as a private business or even an academic or public organization. There's plenty of serious health issues constantly competing for a small pool of smart medical peoples attention and with a limited capital. Genetic tailoring still currently involves a high amount of specialist attention per individual and there is plenty of research and money going into it. I've heard multiple doctors tell me it's the future of medicine. Whether it could use more attention and capital is certainly a good question.
- AtlasBarfed 7y agoBecause I've seen these organizations from the inside. The ripe profits going through drug and device companies, and the fact they can be profitable but not TOO profitable, mean they are full of huge executive structures of overpaid businessmen that stifle investment and certainly block any sort of political progress on American medical costs. I didn't say it was infeasible. It's infeasible in the current investment and oligarchical environment: these companies would be stamped out or blocked from competition. There is lots of opportunities for medium-sized companies to thrive, but the governmental aspects would help to kick start it. All medical treatment is a governmental partnership with private sector at a minimum, in all modern medical establishments. A fundamental change to how medical research and treatment is pursued would take regulatory changes as well as financial prompting by governments. Just let me emphasize: the MBAs that live in American drug and device executives are slime. The bastards that pushed the opioid crisis on America are just the same, they just push different drugs.